

Zenith Drugs Private Limited

Registered Office - K. No. 72/5, Village Muradpura Depalpur, District - Indore, Madhya Pradesh - 453001
Email - zenithtozenith@gmail.com | CIN -U24231MP2000PTC014465 | Phone - 8435501868

Notice of 20th Annual General Meeting

NOTICE is hereby given that the 20th Annual General Meeting of Zenith Drugs Private Limited will be held on Thursday, December 31, 2020 at 11:00 AM at K. No. 72/5, Village Muradpura Depalpur, Madhya Pradesh 453001, to transact the following business:

Ordinary Business:

1. To receive, consider and adopt the audited financial statements of the Company for the financial year ended March 31, 2020 including the audited Balance Sheet as at March 31, 2020, Cash Flow Statement, Statement of Profit and Loss for the year ended March, 31 2020 together with notes to accounts thereto and the Auditors' Report thereon and Boards' Report attached thereto.
2. To consider and if thought fit to pass with or without modification(s) the following resolution as an Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Section 139 and all other applicable provisions, if any, of the Companies Act, 2013 and the Rules framed thereunder as amended from time to time, M/s. VDS & Co., Chartered Accountants, Indore (Firm Registration No. 004029C), be and are hereby appointed as Auditors of the Company to hold office from the conclusion of this Annual General Meeting (AGM) till the conclusion of the AGM to be held in the year 2025, (i.e. for period of 5 years) at such remuneration plus GST, out-of-pocket, traveling and living expenses, etc., as may be mutually agreed between the Board of Directors of the Company and the Auditors."

For and on behalf of the Board of
ZENITH DRUGS PRIVATE LIMITED


SANDEEP BHARADWAJ
DIRECTOR
(DIN: 00539347)

Depalpur, November 30, 2020

Notes:

1. A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE INSTEAD OF HIMSELF. A PROXY NEED NOT BE A MEMBER OF THE COMPANY.
2. THE INSTRUMENT APPOINTING A PROXY IN ORDER TO BE EFFECTIVE SHOULD BE DEPOSITED AT THE REGISTERED OFFICE OF THE COMPANY NOT LESS THAN FORTY-EIGHT HOURS BEFORE THE COMMENCEMENT OF THE ANNUAL GENERAL MEETING.
3. ROUTE MAP OF THE AGM VENUE, PURSUANT TO THE SECRETARIAL STANDARD ON GENERAL MEETINGS, IS ALSO ANNEXED.

ATTENDANCE SLIP
(To be presented at the entrance of the meeting venue)

Annual General Meeting on Thursday, December 31, 2020 at 11:00 AM at K. No. 72/5, Village Muradpura
Depalpur, Madhya Pradesh 453001.

Folio No _____

Name of the Member _____

Signature _____

Name of the Proxyholder _____

Signature _____

1. Only Member/Proxyholder can attend the Meeting.
2. Member/Proxyholder should bring his/her copy of Notice for reference at the Meeting.

A handwritten signature in black ink, appearing to be 'Sundar', written in a cursive style.

Zenith Drugs Private Limited

Registered Office - K. No. 72/5, Village Muradpura Depalpur, District - Indore, Madhya Pradesh - 453001
Email - zenithtozenith@gmail.com | CIN - U24231MP2000PTC014465 | Phone - 8435501868

FORM NO. MGT-11

PROXY Form

[Pursuant to Section 105(6) of the Companies Act, 2013 and rule 19(3) of the Companies (Management and Administration) Rules, 2014]

Name of the Member(s)	
Registered Address	
E-mail Id	
Folio No.	

I/We, being the member(s) of _____ shares of the above named company, hereby appoint

Name	E-mail Id
Address	
Signature _____, or failing him	

Name	E-mail Id
Address	
Signature _____, or failing him	

Name	E-mail Id
Address	
Signature _____, or failing him	

as my/ our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the Annual General Meeting of the company, to be held on Thursday, December 31, 2020 at 11:00 AM at K. No. 72/5, Village Muradpura Depalpur, Madhya Pradesh 453001. and at any adjournment thereof in respect of such resolutions as are indicated below:




Resolution No.	Resolution(s)
1	To receive, consider and adopt the audited financial statements of the Company for the financial year ended March 31, 2020 including the audited Balance Sheet as at March 31, 2020, Cash Flow Statement , Statement of Profit and Loss for the year ended March, 31 2020 together with notes to accounts thereto and the Auditors' Report thereon and Boards' Report attached thereto.
2	Appointment of M/s. VDS & Co., Chartered Accountants (Registration Number 004029C. with the Institute of Chartered Accountants of India), as Auditors.

Signed this _____ day of _____ 20__

Signature of shareholder(s) _____

Signature of proxy holder(s) _____



Note:

1. This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the Meeting.
2. A person can act as proxy on behalf of members not exceeding fifty (50) and holding in the aggregate not more than ten percent of the total share capital of the Company. A member holding more than ten percent of the total share capital of the Company may appoint a single person as a proxy and such person cannot act as a proxy for any other person or shareholder.

Zenith Drugs Private Limited

Registered Office - K. No. 72/5, Village Muradpura Depalpur, District - Indore, Madhya Pradesh - 453001
Email - zenithtozenith@gmail.com | CIN - U24231MP2000PTC014465 | Phone - 8435501868

Boards' Report

Dear Members,

The Board of Directors present the 20th Annual Report together with the audited financial statements of the Company for the Financial Year ended March 31, 2020.

1. STATE OF AFFAIRS, FINANCIAL PERFORMANCE AND FUTURE OUTLOOK:

1.1 Financial Highlights and Summary:

The Financial Results of the Company for the year March, 31 2020 are summarized as under:

Particulars	Current Year (in Rs.) 2019-2020	Previous Year (in Rs.) 2018 - 2019
Revenue from operations	782725641.02	521677325.03
Other Income	620214.00	223034.00
Total Expenses [excluding interest & depreciation]	712266312.93	488577331.12
Profit before Interest, Depreciation & Tax	71079542.09	33323027.91
Less: Depreciation	9184556.00	8059730.00
Less: Finance Cost	13122105.49	9481630.14
Profit / (Loss) Before Tax	48772880.60	15781667.77
Less: Tax Expenses		
1. Current Tax	15147528.00	4611795.00
2. Deferred Tax	-373523.00	-171882.00
Net Profit / (Loss) after Tax	33998875.60	11341754.77
Add: Amount brought forward from Last Year	25716071.77	14374317.00
Balance carried forward to Balance Sheet	59714947.37	25716071.77

1.2 Operations and Future Outlook:


During the year under review, your Company has achieved total revenue and net profit of Rs. 783345855.02 and Rs. 33998875.6 respectively as against total revenue and net profit of Rs. 521900359.03 and Rs. 11341754.77 respectively during the previous financial year ended 31st March, 2019.

Your Directors expects to achieve better performance in the future and are taking maximum efforts to optimize the results in the coming years.

1.3 Change in Nature of Business:

There is no change in the nature of business of your Company during the year under review.

1.4 Changes in Share Capital:



During the year under review, there was no change in the Equity Capital of the Company.

On March 31, 2020, the Authorized Equity Share Capital was Rs.24000000/- and the Issued, Subscribed and Paid-up Equity Share Capital of the Company was Rs. 4000000/-.

None of Directors of the company is holding any instruments convertible into Equity Shares of the Company.

1.5 Revision of Annual Financial Statement:

There was no case of revision in financial statement during the year.

2. EXTRACT OF ANNUAL RETURN:

The Extract of Annual Return as prescribed in form MGT 9 required under section 92 of the Companies Act, 2013 is included in this report as Annexure-1.

3. NUMBER OF MEETINGS OF THE BOARD:

During the Financial Year 2019-2020, the board of the directors duly met 9 times on May 25, 2019, May 29, 2019, June 28, 2019, June 30, 2019, September 5, 2019, September 9, 2019, September 19, 2019, December 2, 2019 and March 19, 2020 respectively for which proper notices for meeting were given and the proceedings were properly recorded. Details of attendances are as under:

S.No.	Name of Director	No. of Board Meeting Held	No. of Board Meeting Attended	Attendance at the previous Annual General Meeting
1.	Ajay Singh Dassundi	9	9	Yes
2.	Bhupesh Soni	9	9	Yes
3.	Poonam Chand Sharma	9	9	Yes
4.	Sandeep Bharadwaj	9	9	Yes

4. DIRECTORS RESPONSIBILITY STATEMENT:

Pursuant to the provisions of Section 134(5) of the Companies Act, 2013, ('the Act') your Directors confirm that:

- in the preparation of the annual accounts for the financial year ended March 31, 2020, the applicable accounting standards had been followed along with proper explanation relating to material departures, if any;
- the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of financial year and of the profit of the Company for that period;
- the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act, for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- the directors had prepared the annual accounts on a going concern basis; and
- the directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

5. REPORTING OF FRAUD BY STATUTORY AUDITORS:

There was no fraud in the Company; hence no reporting was made by statutory auditors of the Company under sub-section (12) of section 143 of the Companies Act, 2013.

6. APPOINTMENT AND STATEMENT ON DECLARATION BY INDEPENDENT DIRECTOR:

Being a Private Limited company there is no requirement to appoint any Independent Directors pursuant to provision of Section 149 (6) and read with 149 (10) of the Companies Act, 2013.

7. NOMINATION, REMUNERATION COMMITTEE AND STAKEHOLDERS RELATIONSHIP COMMITTEE:

Being a Private Limited Company there is no requirement to constitute any Nomination and Remuneration Committee under Section 178 (1) of the Companies Act, 2013 and Rule 6 of the Companies (Meetings of Board and its Powers) Rules, 2014 and Stakeholders Relationship Committee under Section 178 (5) of the Companies Act, 2013.

8. STATUTORY AUDIT AND AUDITORS REPORT:

The Auditors of the Company, M/s. VDS & Co., Chartered Accountants, Indore hold office until the ensuing Annual General Meeting. The said Auditors have furnished the certificate of their eligibility for re-appointment.

In terms of the provisions of Section 139 of the Companies Act, 2013 and other applicable provisions, if any of the Companies Act, 2013, it is proposed to appoint M/s. VDS & Co., Chartered Accountants, Indore (Firm Registration No. 004029C) the retiring auditor as statutory auditors of the Company from the conclusion of this Annual General Meeting till the conclusion of Annual General Meeting to be held in the year 2025 (i.e. for a period of 5 years) on such remuneration as may be decided and fixed by the Board.

Comments on Auditor's Report

The comments on statement of accounts referred to in the report of the auditors are self explanatory. The Auditors' Report does not contain any qualification, reservation or adverse remark.

9. COST RECORD AND/OR COST AUDIT:

During the year the Company has properly made and maintained cost records as per provisions of Section 148 of Company's Act, 2013 read with the Companies (Cost records & Audit) Rules, 2014 and provisions of cost audit are also applicable for the FY 2019-20.

10. SECRETARIAL AUDIT REPORT:

Being a Private Limited Company, requirements of the provisions of Section 204 of the Companies Act, 2013 read with Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, is not applicable.

11. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS BY COMPANY:

The Company has not advanced any loans, provided any guarantee, or made investment under section 186 of the Companies Act, 2013 during the period under review.

12. PARTICULARS OF CONTRACTS AND ARRANGEMENTS WITH RELATED PARTIES:

All related party transactions that were entered into during the Financial Year were on arm's length basis and were in the ordinary course of business and the material transactions are reported in Form AOC-2 attached herewith.

The details of related party transactions are set out in the notes to the financial statements.

13. AMOUNT TRANSFER TO RESERVE:

During the year under review, your Company has not transferred any sum to General Reserve.

14. DIVIDEND:

Your Directors have not recommended any Dividend for the year under review.

15. MATERIAL CHANGES & COMMITMENTS, IF ANY AFFECTING THE FINANCIAL POSITION OF THE COMPANY:

There were no material changes and commitments affecting the financial position of the Company between the end of financial year and the date of this Report.

16. PARTICULARS OF CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNING AND OUTGO:

i. Conservation of Energy:

a. The steps taken or impact on conservation of energy:-

possible saving of energy.

- b. The steps taken by the company for utilizing alternate sources of energy:-
The Company has used alternate source of energy, whenever and to the extent possible
- c. The capital investment on energy conservation equipments:- NIL

ii. Technology Absorption:

- a. The effort made towards technology absorption:-
No specific activities have been done by the Company.
- b. The benefits derived like product improvement, cost reduction, product development or import substitution:-
No specific activity has been done by the Company
- c. In case of imported technology (imported during the last three years reckoned from the beginning of the financial year):- NA
- d. The expenditure incurred on Research & Development:- NIL

iii. Foreign Exchange Earnings and Outgo:

The Details of Foreign Exchange earnings and outgo during the financial year as required by the Companies (Accounts) Rules, 2014 is provided as following:-

S.No.	Particulars	Current Year (in Rs.)	Previous Year (in Rs.)
(a)	Foreign exchange earnings	0.00	0.00
(b)	Foreign exchange outgo	0.00	0.00

17. STATEMENT INDICATING DEVELOPMENT & IMPLEMENTATION OF RISK MANAGEMENT POLICY:

The Board of Directors of the Company state that risk associated in the ordinary course of business is duly taken care by the Board while taking business decisions. Further the company need not required to formulate any specified risk management policy.

18. CORPORATE SOCIAL RESPONSIBILITY:

The company is not required to provide statement on Corporate Social Responsibility as per Section 134 (3) (o) of the Companies Act, 2013 as the company do not fall under the criteria provided under section 135 (1) of the Companies Act, 2013 therefore no such committee was constituted.

19. ANNUAL EVALUATION OF PERFORMANCE OF THE BOARD:

The Company, being a Private Limited Company was not required to carry formal annual evaluation by the Board of its own performance and that of its committees and individual directors pursuant to Section 134 (3) (p) of the Companies Act, 2013 and Rule 8 (4) of the Companies (Accounts) Rules, 2014. Although, the directors of the Company are vigilant towards their duties and responsibilities as director of the Company.

20. DIRECTORS & KEY MANAGERIAL PERSONNEL:

During the year there was no change in the constitution of the board of the directors of the Company.

In view of the status of the Company it is not required to appoint any key managerial personnel under the provisions of section 203 of the Companies Act, 2013 and rules made there under.

Disqualifications of Directors:

During the year declarations received from the Directors of the Company pursuant to Section 164 of the Companies Act, 2013. Board appraised the same and found that none of the director is disqualified for holding office as director.

21. SUBSIDIARY, ASSOCIATE COMPANIES OR JOINT VENTURE:



The Company does not have any subsidiary company or associate company or any joint venture company; hence Form AoC-1 is not applicable.

22. DEPOSITS:

During the year the Company has not accepted any deposits, within the meaning of Section 73 of the Companies Act, 2013, read with the Companies (Acceptance of Deposits) Rules, 2014.

However the details of unsecured loan received from directors and their relatives during the year are given in notes to the Financial Statements.

23. SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS:

There are no significant material orders passed by the Regulators/Courts/Tribunals impacting the going concern status of the Company and its future operations.

24. INTERNAL CONTROL SYSTEM AND THEIR ADEQUACY:

Your directors confirm having laid down internal financial controls and that such internal financial controls are adequate and were operating effectively.

25. AUDIT COMMITTEE:

Being a private Limited Company provisions of section 177 (1) of the Companies Act, 2013 is not applicable to the company; hence there is no requirement for constituting an Audit Committee

26. ESTABLISHMENT OF VIGIL MECHANISM:

Provisions of Section 177 (10) of the Companies Act, 2013 for establishment of Vigil Mechanism are not applicable to the Company. However, Management of the Company has established the mechanism which provides for the adequate safeguards against victimization.

27. COMMISSION RECEIVED BY DIRECTORS FROM HOLDING/SUBSIDIARY:

There is no holding or subsidiary company of the company.

28. PARTICULARS OF EMPLOYEES:

None of the employee of the company is drawing more than Rs.1,02,00,000/- per annum or Rs.8,50,000/- per month for the part of the year, during the year under review therefore Particulars of the employees as required under Section 197 of the Companies Act, 2013 read with rule 5 (2) & rule 5 (3) of the Companies (Appointment and Remuneration) Rules, 2014 are not applicable, during the year under review.

29. VOTING RIGHTS OF EMPLOYEES:

During the year under review the company has not given loan to any employee for purchase of its own shares as per section 67 (3) (c) of the Companies Act, 2013. Therefore the company not required to made disclosure as per rule 6 (4) of the Companies (Share Capital and Debentures) Rules, 2014.

30. DISCLOSURE REGARDING ISSUE OF EMPLOYEE STOCK OPTIONS:

The Company does not have issued shares under employee's stock options scheme pursuant to provisions of Section Rule 12(9) of the Companies (Share Capital and Debenture) Rules, 2014, so question does not arise about voting rights not exercised by employee.

31. DISCLOSURE REGARDING ISSUE OF SWEAT EQUITY SHARES:

The Company does not have issued sweat equity shares pursuant to provisions of Section 54 read with Rule 8 of the Companies (Share Capital and Debenture) Rules, 2014 during the Financial Year.

32. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013:

The Company has zero tolerance for sexual harassment at workplace and has adopted a Policy on Prevention, Prohibition and Redressal of Sexual Harassment at the Workplace, in line with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules made there under. The Policy aims to provide protection to employees at the workplace and prevent and redress complaints of sexual harassment and for matters connected or incidental thereto, with the objective of providing a safe working environment, where employees feel secure.

During the year under review, the Company has not received any complaint from any woman employee.

33. ENVIRONMENT AND SAFETY:

The Company is conscious about the importance of environmentally clean and safe operations. The



Company's policy required conduct of operations in such a manner, so as to ensure safety of all concerned, compliances environmental regulations and preservation of natural resources.


34. INDUSTRIAL RELATIONS:


Company's Industrial relations continued to be healthy, cordial and harmonious during the period under review.

35. ACKNOWLEDGEMENT:

Your Directors would like to thank all stakeholders, namely customers, shareholders, dealers, suppliers, bankers, employees and all other business associates for the continuous support given by them to the Company and its Management.

For Zenith Drugs Private Limited


Sandeep Bharadwaj
Director
(DIN: 00539347)


Bhupesh Soni
Director
(DIN: 00539355)

November 30, 2020
Depalpur

**Form No. MGT-9
Extract of Annual Return**

Pursuant to Section 92 (3) of the Companies Act, 2013 and rule 12(1) of the Company (Management & Administration) Rules, 2014

As on Financial Year ended on March 31, 2020

I. REGISTRATION & OTHER DETAILS:

1. CIN	U24231MP2000PTC014465
2. Registration Date	15/11/2000
3. Name of the Company	Zenith Drugs Private Limited
4. Category/Sub-category of the Company	Private
5. Address of the Registered office & contact details	K. No. 72/5, Village Muradpura Depalpur, District - Indore, Madhya Pradesh - 453001
6. Whether listed company	Unlisted
7. Name, Address & contact details of the Registrar & Transfer Agent, if any.	-

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY (All the business activities contributing 10 % or more of the total turnover of the company shall be stated)

S.No.	Name and Description of main products / services	NIC Code of the Product/Service	% to total turnover of the company
1.	Manufacture of pharmaceuticals, medicinal chemical and botanical products	2100	100.00

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES -

S.No.	Name of the Company	Address of the company	CIN/GLN	Holding/ Subsidiary/ Associate	% of Shares held	Applicable Section
-	-	-	-	-	-	-

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

1. Category-wise Share Holding	As per Attachment A
2. Shareholding of Promoter	As per Attachment B
3. Change in Promoters' Shareholding	As per Attachment C
4. Shareholding Pattern of top ten Shareholders (Other than Directors, Promoters and Holders of GDRs and ADRs)	As per Attachment D
5. Shareholding of Directors and Key Managerial Personnel	As per Attachment E

V. INDEBTEDNESS

Sandeep


Indebtedness of the Company including interest outstanding/accrued but not due for payment	As per Attachment F
--	---------------------


VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

A.	Remuneration to Managing Director, Whole-time Directors and/or Manager	As per Attachment G
B.	Remuneration to other directors	As per Attachment H
C.	Remuneration to Key Managerial Personnel other than MD/MANAGER/WTD	As per Attachment I

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES As per Attachment J

For Zenith Drugs Private Limited


Sandeep Bharadwaj
Director
(DIN: 00539347)


Bhupesh Soni
Director
(DIN: 00539355)

November 30, 2020
Depalpur

Attachment A

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

1. Category-wise Share Holding (01/04/2019 to 31/03/2020)

Sl. No.	Category of Shareholders	No. of Shares held at the beginning of the year				No. of Shares held at the end of the year				% Change During the year
		Demat	Physical	Total	% of Total	Demat	Physical	Total	% of Total	
A	Promoters									
(1)	Indian									
a)	Individual / HUF	0	400000	400000	100	0	400000	400000	100	0
b)	Central Govt.	0	0	0	0.00	0	0	0	0.00	0.00
c)	State Govt (s)	0	0	0	0.00	0	0	0	0.00	0.00
d)	Bodies Corp.	0	0	0	0	0	0	0	0	0
e)	Banks / FI	0	0	0	0.00	0	0	0	0.00	0.00
f)	Any Other	0	0	0	0	0	0	0	0	0
	Sub-total (A) (1)	0	400000	400000	100	0	400000	400000	100	0
(2)	Foreign									
a)	NRIs - Individuals	0	0	0	0	0	0	0	0	0
b)	Other - Individuals	0	0	0	0	0	0	0	0	0
c)	Bodies Corp.	0	0	0	0	0	0	0	0	0
d)	Banks / FI	0	0	0	0.00	0	0	0	0.00	0.00
e)	Any Other	0	0	0	0.00	0	0	0	0.00	0.00
	Sub-total (A) (2)	0	0	0	0	0	0	0	0	0
	Total shareholding of Promoter (A) = (A)(1)+(A)(2)	0	400000	400000	100	0	400000	400000	100	0
B	Public Shareholding									
(1)	Institutions									
a)	Mutual Funds	0	0	0	0.00	0	0	0	0.00	0.00
b)	Banks / FI	0	0	0	0.00	0	0	0	0.00	0.00
c)	Central Govt.	0	0	0	0.00	0	0	0	0.00	0.00
d)	State Govt. (s)	0	0	0	0.00	0	0	0	0.00	0.00
e)	Venture Capital Funds	0	0	0	0.00	0	0	0	0.00	0.00
f)	Insurance Companies	0	0	0	0.00	0	0	0	0.00	0.00
g)	FIs	0	0	0	0.00	0	0	0	0.00	0.00
h)	Foreign Venture Capital Funds	0	0	0	0.00	0	0	0	0.00	0.00
i)	Others (specify)	0	0	0	0.00	0	0	0	0.00	0.00
	Sub-total (B)(1)	0	0	0	0.00	0	0	0	0.00	0.00
(2)	Non- Institutions									
a)	Bodies Corp.									
	i) Indian	0	0	0	0	0	0	0	0	0
	ii) Overseas	0	0	0	0	0	0	0	0	0
b)	Individuals									
	i) Individual shareholders holding nominal share capital upto Rs.1 lakh	0	0	0	0	0	0	0	0	0
	ii) Individual shareholders holding nominal share capital in excess of Rs. 1 lakh	0	0	0	0	0	0	0	0	0
c)	Others (specify)	0	0	0	0	0	0	0	0	0
	Sub-total (B)(2)	0	0	0	0	0	0	0	0	0
	Total Public Shareholding (B)=(B)(1)+(B)(2)	0	0	0	0	0.00	0	0	0	0
C	Shares held by Custodian for GDRs & ADRs	0	0	0	0.00	0.00	0	0	0.00	0.00
	Grand Total (A+B+C)	0	400000	400000	100	0	400000	400000	100	0

Sanjay

Attachment B**IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)****2. Shareholding of Promoters (01/04/2019 to 31/03/2020)**

Sl. No.	Shareholders Name	Shareholding at the beginning of the year			Shareholding at the end of the year			% change in shareholding during the year
		Number of Shares	% of total Shares of the company	% of Shares Pledged/encumbered to total shares	Number of Shares	% of total Shares of the company	% of Shares Pledged/encumbered to total shares	
1	Bhupesh Soni	78730	19.68%	0.00%	78730	19.68%	0.00%	0%
2	Saroj Soni	38050	9.51%	0.00%	38050	9.51%	0.00%	0%
3	Ajay Singh Dassundi	114690	28.67%	0.00%	114690	28.67%	0.00%	0%
4	Arjun Singh Dassundi	6200	1.55%	0.00%	6200	1.55%	0.00%	0%
5	Rajendra S. Dasundi	7800	1.95%	0.00%	7800	1.95%	0.00%	0%
6	Sandeep Bharadwaj	122030	30.51%	0.00%	122030	30.51%	0.00%	0%
7	Jaywanti Soni	16800	4.2%	0.00%	16800	4.2%	0.00%	0%
8	Anjali Dassundi	4600	1.15%	0.00%	4600	1.15%	0.00%	0%
9	Priyanka Bharadwaj	11100	2.78%	0.00%	11100	2.78%	0.00%	0%



Attachment C

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

3. Change in Promoters Shareholding (01/04/2019 to 31/03/2020)

Sl. No.	Name of Promoters	Shareholding at the beginning (01/04/2019) end of the year (31/03/2020)		Date	Increase in share holding	Decrease in share holding	Reason	Cumulative Shareholding during the year (01/04/2019) to (31/03/2020)	
		Number of Shares	% of total Shares of the company					Number of Shares	% of total Shares of the company
1	Ajay Singh Dassundi	114690	28.67%	01/04/2019			Nil Movement		
		114690	28.67%	31/03/2020				114690	28.67%
2	Sandeep Bharadwaj	122030	30.51%	01/04/2019			Nil Movement		
		122030	30.51%	31/03/2020				122030	30.51%
3	Bhupesh Soni	78730	19.68%	01/04/2019			Nil Movement		
		78730	19.68%	31/03/2020				78730	19.68%
4	Saroj Soni	38050	9.51%	01/04/2019			Nil Movement		
		38050	9.51%	31/03/2020				38050	9.51%
5	Arjun Singh Dassundi	6200	1.55%	01/04/2019			Nil Movement		
		6200	1.55%	31/03/2020				6200	1.55%
6	Rajendra S. Dasundi	7800	1.95%	01/04/2019			Nil Movement		
		7800	1.95%	31/03/2020				7800	1.95%
7	Jaywanti Soni	16800	4.2%	01/04/2019			Nil Movement		
		16800	4.2%	31/03/2020				16800	4.2%
8	Priyanka Bharadwaj	11100	2.78%	01/04/2019			Nil Movement		
		11100	2.78%	31/03/2020				11100	2.78%
9	Anjali Dassundi	4600	1.15%	01/04/2019			Nil Movement		
		4600	1.15%	31/03/2020				4600	1.15%

Sandeep

Attachment D

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

4. Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs) (01/04/2019 to 31/03/2020)

Sl. No.	Name of Shareholders	Shareholding at the beginning (01/04/2019) end of the year (31/03/2020)		Date	Increase in share holding	Decrease in share holding	Reason	Cumulative Shareholding during the year (01/04/2019) to (31/03/2020)	
		Number of Shares	% of total Shares of the company					Number of Shares	% of total Shares of the company
Nil									

Sunder

Attachment E

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

5. Shareholding of Directors and Key Managerial Personnel (01/04/2019 to 31/03/2020)

Sl. No.	Name of Directors & KMP	Shareholding at the beginning (01/04/2019) end of the year (31/03/2020)		Date	Increase in share holding	Decrease in share holding	Reason	Cumulative Shareholding during the year (01/04/2019) to (31/03/2020)	
		Number of Shares	% of total Shares of the company					Number of Shares	% of total Shares of the company
1	Ajay Singh Dassundi	114690	28.67%	01/04/2019			Nil Movement		
		114690	28.67%	31/03/2020				114690	28.67%
2	Sandeep Bharadwaj	122030	30.51%	01/04/2019			Nil Movement		
		122030	30.51%	31/03/2020				122030	30.51%
3	Bhupesh Soni	78730	19.68%	01/04/2019			Nil Movement		
		78730	19.68%	31/03/2020				78730	19.68%
4	Poonam Chand Sharma	0	0%	01/04/2019			Nil Movement		
		0	0%	31/03/2020				0	0%

Sandeep

Attachment - F

Indebtedness of the Company including interest outstanding/accrued but not due for payment

V. INDEBTEDNESS (01/04/2019 to 31/03/2020)

Particulars	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year				
i) Principal Amount	53045483.88	40972867.00	0.00	94018350.88
ii) Interest due but not paid	0.00	0.00	0.00	0
iii) Interest accrued but not due	0.00	0.00	0.00	0
Total (i+ii+iii)	53045483.88	40972867	0	94018350.88
Change in Indebtedness during the financial year				
* Addition	29116420.66	27413552.43	0.00	56529973.09
* Reduction	11130937.57	18411224.62	0.00	29542162.19
Net Change	17985483.09	9002327.81	0	26987810.9
Indebtedness at the end of the financial year				
i) Principal Amount	71030966.97	49975194.81	0.00	121006161.78
ii) Interest due but not paid	0.00	0.00	0.00	0
iii) Interest accrued but not due	0.00	0.00	0.00	0
Total (i+ii+iii)	71030966.97	49975194.81	0	121006161.78

Sandeep

Attachment G

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL-

A. Remuneration to Director, Managing Director, Whole-time Directors and/or Manager:

S.No.	Name of D/ MD/ WTD/ Manager	Particulars of Remuneration										Total Amount
		Gross Salary	Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	Value of perquisites u/s 17(2) Income-tax Act, 1961	Profits in lieu of salary under section 17(3) Income-tax Act, 1961	Stock Option	Sweat Equity	Commission - as % of profit - others, specify...	Others, please specify	Total (A)	Ceiling as per the Act	
1	Sandeep Bharadwaj Director	6800000	6800000	0	0	0	0	0	0	6800000	NA	6800000
2	Bhupesh Soni Director	5600000	5600000	0	0	0	0	0	0	5600000	NA	5600000
3	Ajay Singh Dassundi Director	2306000	2306000	0	0	0	0	0	0	2306000	NA	2306000
	Total	14706000	14706000	0	0	0	0	0	0	14706000	NA	14706000

Attachment H

B. Remuneration to other directors

S.No.	Name of D/ MD/ WTD/ Manager	Particulars of Remuneration										Overall Ceiling as per the Act
		Independent Directors				Other Non-Executive Directors				Total (B)=(1+2)	Total Managerial Remuneration	
Fee for attending board committee meetings	Commission	Others, please specify	Total (1)	Fee for attending board committee meetings	Commission	Others, please specify	Total (2)					
-	-	-	-	-	-	-	-	-	-	-	-	-
	Total	-	-	-	-	-	-	-	-	-	-	-

Attachment I

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD

S.No.	Key Managerial Personnel	Particulars of Remuneration									
		Gross salary			Stock Option	Sweat Equity	Commission	Others, please specify	Total	as % of profit	others, specify...
(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	(c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961									
1.	CEO	-	-	-	-	-	-	-	-	-	-
2.	CS	-	-	-	-	-	-	-	-	-	-
3.	CFO	-	-	-	-	-	-	-	-	-	-
	Total	-	-	-	-	-	-	-	-	-	-


Attachment J


VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Sandeep

Type	Section of the Companies Act	Brief Description	Details of Penalty / Punishment/ Compounding fees imposed	Authority [RD / NCLT/ COURT]	Appeal made, if any (give Details)
A. COMPANY					
Penalty	-	-	-	-	-
Punishment	-	-	-	-	-
Compounding	-	-	-	-	-
B. DIRECTORS					
Penalty	-	-	-	-	-
Punishment	-	-	-	-	-
Compounding	-	-	-	-	-
C. OTHER OFFICERS IN DEFAULT					
Penalty	-	-	-	-	-
Punishment	-	-	-	-	-
Compounding	-	-	-	-	-

For Zenith Drugs Private Limited


Sandeep Bharadwaj
Director
(DIN: 00539347)


Bhupesh Soni
Director
(DIN: 00539355)

November 30, 2020
Depalpur

Form AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso thereto


1. Details of contracts or arrangements or transactions not at arm's length basis

Name(s) of the related party and nature of relationship	Nature of contracts / arrangements / transactions	Duration of the contracts / arrangements / transactions	Salient terms of the contracts or arrangements or transactions including the value, if any	Justifications for entering contracts or arrangement or transactions not at arm's length basis	Date(s) of approval by the Board, if any	Amount paid as advances, if any	Date on which the special resolution was passed in general meeting as required under first proviso to section 188
(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)

Sandya

2. Details of material contracts or arrangement or transactions at arm's length basis							
Name(s) of the related party	Nature of relationship	Nature of contracts/arrangements/ transactions	Duration of the contracts / arrangements / transactions	Salient terms of the contracts or arrangements or transactions	Value of transactions (Rs.)	Date(s) of approval by the Board, if any	Amount paid as advances, if any (in Rs.)
(a)		(b)	(c)	(d)		(e)	(f)
M/s Probiotech	Director's Partnership Firm	Purchase	Ongoing	Purchase	Rs. 6,26,24,536/-	25/05/2019	

For Zenith Drugs Private Limited


Sandeep Bharadwaj
Director
(DIN: 00539347)


Bhupesh Soni
Director
(DIN: 00539355)



Independent Auditor's Report

To,
The Members,
ZENITH DRUGS PVT. LTD.

Report on the audit of the financial statements

Opinion

We have audited the accompanying financial statements of M/S ZENITH DRUGS PVT. LTD. ("the Company"), which comprise the balance sheet as at March 31, 2020, and the Statement of Profit and Loss and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ('Act') in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2020, its Profit and cash flows for the year ended on that date.

Basis for opinion

We conducted our audit in accordance with the standards on auditing specified under section 143 (10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Company in accordance with the code of ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the code of ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters


Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Reporting of key audit matters as per SA 701, Key Audit Matters are not applicable to the Company as it is an unlisted company.

Information other than the financial statements and auditors' report thereon

The Company's board of directors is responsible for the preparation of the other information. The other information comprises the information included in the Board's Report including Annexures to Board's Report, Business Responsibility Report but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.



In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Management's responsibility for the financial statements

The Company's board of directors are responsible for the matters stated in section 134 (5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.


In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The board of directors are also responsible for overseeing the Company's financial reporting process.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures



in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, and on the basis of such checks as we considered appropriate and in the terms of information and explanation given to us and as they relate to the company, We enclose an Annexure A, a statement on the matters specified in the paragraph 3 and 4 of the said order to the extent applicable the company.

2. As required by Section 143 (3) of the Act, we report that:

(a) we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

(b) in our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;

(c) the balance sheet, the statement of Profit and Loss and Cash Flow Statement dealt with by this Report are in agreement with the books of account;


(d) in our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014;

(e) on the basis of the written representations received from the directors as on 31 March 2020 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2020 from being appointed as a director in terms of Section 164 (2) of the Act;

(f) Company have been exempted by Ministry of Corporate Affairs for reporting requirements under Section 143(3)(i) on adequacy of Internal Financial Control System vide its notification dated 13th June, 2017.

(g) with respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

i. the Company does not have any pending litigation which would impact its financial position;




ii. the Company has made provision, as required under the applicable law or accounting standards, for material foreseeable losses, if any, on long-term contracts including derivative contracts;

iii. There has been no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

PLACE : INDORE
DATED : 30.11.2020

FOR V D S & CO.
CHARTERED ACCOUNTANTS
FRN 004029C
INDORE.
M. S. DHING
PARTNER
M.No.075588



Annexure - A to the Auditors' Report

The Annexure referred to in Independent Auditors' Report to the members of the Company on the standalone financial statements for the year ended 31 March 2020, we report that:

i. (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.

(b) The Company has a regular programme of physical verification of its fixed assets by which fixed assets are verified in a phased manner. In accordance with this programme, certain fixed assets were verified during the year and no material discrepancies were noticed on such verification. In our opinion, this periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets.

(c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties are held in the name of the company.

ii. The management has conducted physical verification of inventory at reasonable intervals during the year and no material discrepancies were noticed on such physical verification.

iii. According to the information and explanations given to us, the Company has not granted any loans, secured or unsecured to companies, firms, LLP or other parties covered in the register maintained under section 189 of the Companies Act, 2013 ('the Act'). Accordingly, the provisions of clause 3(iii)(a), (b) & (c) of the order are not applicable to the company and hence not commented upon.

iv. In our opinion and according to the information and explanations given to us, there are no loans, investments, guarantee, and securities granted in respect of which provisions of section 185 and 186 of the Companies Act, 2013 are applicable and hence not commented upon.

v. The Company has not accepted any deposits from the public.


vi. The Central Government has prescribed the maintenance of cost records under section 148(1) of the Act, is applicable to Company.

vii. (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted/accrued in the books of account in respect of undisputed statutory dues including provident fund, income-tax, sales tax, value added tax, duty of customs, service tax, cess, goods and service tax and other material statutory dues have been regularly deposited during the year by the Company with the appropriate authorities. As explained to us, the Company did not have any dues on account of employees' state insurance and duty of excise. According to the information and explanations given to us, no undisputed amounts payable in respect of, income tax, sales tax, value added tax, duty of customs, service tax, cess, goods and service tax and other material statutory dues were in arrears as at 31 March 2020 for a period of more than six months from the date they became payable except professional tax and TDS.

(b) According to the information and explanations given to us, there are no material dues outstanding towards Custom Duty, Income Tax, Sales Tax, Excise Duty, Service Tax, Goods and Service Tax and VAT except the after assessment demand of CST for the financial year 2015-16 Rs.205639.00 is not yet paid for the want of pending "C" forms.



viii. In our opinion and according to the information and explanations given by the management, company has not defaulted in repayment of dues to bank or debenture holders. The company did not any dues to in respect of loans and borrowing payable financial institution or government.

ix. The Company did not raise any money by way of initial public offer or further public offer (including debt instruments) and term loans during the year. Accordingly, paragraph 3 (ix) of the Order is not applicable.



- x. According to the information and explanations given to us, no material fraud by the Company or on the Company by its officers or employees has been noticed or reported during the course of our audit.
- xi. According to the information and explanations give to us and based on our examination of the records of the Company, the Company has paid/provided for managerial remuneration in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Act.
- xii. In our opinion and according to the information and explanations given to us, the Company is not a nidhi company. Accordingly, paragraph 3(xii) of the Order is not applicable.
- xiii. According to the information and explanations given to us and based on our examination of the records of the Company, transactions with the related parties are in compliance with sections 177 and 188 of the Act where applicable and details of such transactions have been disclosed in the financial statements as required by the applicable accounting standards.
- xiv. According to the information and explanations give to us and based on our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year.
- xv. According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not entered into non-cash transactions with directors or persons connected with him. Accordingly, paragraph 3(xv) of the Order is not applicable.
- xvi. The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act 1934.

PLACE : INDORE
DATED : 30.11.2020

FOR V D S & CO.
CHARTERED ACCOUNTANTS
FRN 004029C


INDORE
(D.S. DHING)
PARTNER
M.No.075588

CIN No.- U24231MP2000PTC014465
BALANCE SHEET AS AT 31st MARCH, 2020


Particulars	Note No.	31.03.2020 Rs.	31.03.2019 Rs.
I. EQUITY AND LIABILITIES			
1 Shareholders' funds			
(a) Share capital	2	4,000,000.00	4,000,000.00
(b) Reserves and surplus	3	61,714,947.37	27,716,071.77
2 Non-current liabilities			
(a) Long-term borrowings	4	96,226,071.96	73,954,289.59
(b) Deferred tax liabilities (Net)	5	1,075,175.00	1,448,698.00
3 Current liabilities			
(a) Short-term borrowings	6	24,506,418.76	20,064,061.29
(b) Trade payables	7	230,033,235.53	178,378,262.00
(c) Short-term provisions	8	19,683,847.77	4,720,583.70
TOTAL		437,239,696.39	310,281,966.35
II. ASSETS			
1 Non-current assets			
(a) Fixed assets	9	63,970,045.10	49,949,362.00
(i) Capital Work in Progress		26,098,548.20	
(b) Other Non Current Assets	10	-	12,000.00
2 Current assets			
(a) Current investments		-	-
(b) Inventories	11	43,629,005.00	48,885,711.00
(c) Trade receivables	12	254,339,794.96	170,531,932.75
(d) Cash and cash equivalents	13	4,356,665.86	5,306,314.96
(e) Short-term loans and advances	14	44,845,637.27	35,596,645.64
TOTAL		437,239,696.39	310,281,966.35

As per our report of Even Date attached

UDIN: 20075588AAAAAT5379

For V D S & Company

Chartered Accountants



(D.S. DHING)

Partner

M.No. 075588

Firm Regn No. 4029C

Place: Indore

Date : 30/11/2020

For and On Behalf Of the Board Of Director
for ZENITH DRUGS PVT. LTD. for ZENITH DRUGS PVT. LTD.

(Sandeep Bhardwaj)
DIRECTOR

SANDEEP BHARDWAJ

Director

(DIN: 00539347)

(Bhupesh Sonar)
DIRECTOR

BHUPEESH SONAR

Director

(DIN: 00539355)

STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDING 31ST MARCH, 2020

Particulars	Refer Note No.	31.03.2020	31.03.2019
		Rs.	Rs.
I. Revenue From Operations			
Sale of products	15	775,177,306.64	521,677,325.03
Other operating revenues		7,548,334.38	-
		<u>782,725,641.02</u>	<u>521,677,325.03</u>
II. Other income	16	620,214.00	223,034.00
III. Total Revenue (I + II)		<u>783,345,855.02</u>	<u>521,900,359.03</u>
IV. Expenses:			
Cost of Materials Consumed	17	536,399,756.46	402,865,418.23
Changes in inventories of Stock-in-Trade	18	3,775,783.00	(25,520,420.00)
Employee benefits expense	19	38,701,226.00	26,560,469.00
Direct Exp.	20	26,447,967.73	23,791,939.84
Finance costs	21	13,122,105.49	9,481,630.14
Depreciation and amortization expense	9	9,184,556.00	8,059,730.00
Other expenses	22	106,941,579.74	60,879,924.05
Total expenses		<u>734,572,974.42</u>	<u>506,118,691.26</u>
V. Profit before tax		<u>48,772,880.60</u>	<u>15,781,667.77</u>
VI Tax expense:			
(1) Current tax		15,147,528.00	4,611,795.00
(2) Deferred tax		(373,523.00)	(171,882.00)
(3) Earlier Year Tax Expense		-	-
		<u>14,774,005.00</u>	<u>4,439,913.00</u>
VII Profit (Loss) for the period		<u>33,998,875.60</u>	<u>11,341,754.77</u>
VIII Earnings per equity share:			
Basic and Diluted	23	85.00	28.35

As per our report of Even Date attached

For V D S & Company
Chartered Accountants(D.S. DHING)
Partner

M.No. 075588

Firm Regn No. 4029C

Place: Indore

Date : 30/11/2020

For and On Behalf of the Board Of Director
ZENITH DRUGS PVT. LTD.

SANDEEP BHARDWAJ
Director
(DIN: 00539347)

BHUPESH SONI
Director
(DIN: 00539355)



CASH FLOW STATEMENT FOR THE YEAR 2019-20

(Amount in Rs.)

1	CASH FLOW FROM OPERATING ACTIVITIES	31st March, 2020	31st March, 2019
	Net Profit before taxation and extraordinary item	48,772,881	15,781,668
	<u>Adjustment for:</u>		
	Depreciation	9,184,556	8,059,730
	Interest Paid	13,122,105	9,481,630
	Interest received	-	-
	Dividend Received	-	-
	Profit/Loss on Sale of assets	-	-
	Profit/Loss on Sale of investments	-	-
	Provision for leave encashment and gratuity	-	-
	Provision for Diminution in value of Shares	-	-
	Miscellaneous Balance written off	12,000	12,000
	Inventory written off	-	-
	Operating Profit before Working Capital Changes	71,091,542	33,335,028
	Increase/Decrease in Inventory	5,256,706	(25,520,420)
	Increase/Decrease in Trade and Other Receivables	(83,807,862)	(31,021,125)
	Increase/Decrease in Short Term Loan and Advances	(9,248,992)	(18,937,893)
	Increase/Decrease in Trade Payables	66,618,238	30,510,147
	Cash generated from Operations	49,909,632	(11,634,263)
	Income Tax	(15,147,528)	(4,611,795)
	NET CASH FLOW FROM OPERATING ACTIVITIES	34,762,104	(16,246,058)
2	CASH FLOW FROM INVESTING ACTIVITIES		
	Sale of investment	-	-
	Interest received	-	-
	Dividend received	-	-
	Purchase of Fixed Assets	(49,303,787)	(4,266,558)
	Issued Share Capital and Security Premium	-	-
	Purchase of Investment	-	-
	Sale of Asset	-	-
	NET CASH FLOW FROM INVESTING ACTIVITIES	(49,303,787)	(4,266,558)
3	CASH FLOW FROM FINANCING ACTIVITIES		
	Increase/Decrease in Term Loan	22,271,782	28,561,854
	Increase/Decrease in WC	4,442,357	5,524,107
	Interest Paid	(13,122,105)	(9,481,630)
	NET CASH FLOW FROM FINANCING ACTIVITIES	13,592,034	24,604,331
	NET INCREASE IN CASH AND CASH EQUIVALENTS	(949,649)	4,091,715
	Cash and Cash Equivalents at the beginning of the period	5,306,315	1,214,600
	Cash and Cash Equivalents at the end of the period	4,356,666	5,306,315

1. Figures in minus represents Cash outflows

2. Cash & Cash equivalents represents Cash & Bank Balances only

As per our report of Even Date attached

For V D S & Company
Chartered Accountants

(D. S. DHING)

Partner

M. No. 075588

Firm Regn No. 4029C

Place: Indore

Date : 30/11/2020

For ZENITH DRUGS PVT. LTD. On Behalf Of the Board Of Director

Sandeep Bhardwaj
DIRECTOR

SANDEEP BHARDWAJ

Director

(DIN: 00539347)

Bhupesh Soni
DIRECTORBHUPESH SONI
Director

(DIN: 00539355)

ZENITH DRUGS (P) LIMITED
CIN No.- U24231MP2000PTC014465
YEAR ENDED 31ST MARCH, 2020

NOTE 1:SIGNIFICANT ACCOUNTING POLICIES.

1 Corporate Information

The Company is engaged In the business of Pharmaceuticals.

2 Basis of Preparation

The financial statements of the Company have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) to comply with the Accounting Standards notified under the Companies (Accounting Standards) specified under sec 133 of the Companies Act, 2013. Read with Rule 7 of the compnies accounts rule, 2014 and the relevent provision of the Compnies Act,2013 .The financial statements have been prepared on accrual basis. The accounting policies adopted in the preparation of the financial statements are consistent with those followed in the previous year.

3 Use of estimates

The Preparation of financial statement in conformity with the Indian GAAP requires judgement , estimates and assumption to be made that effect the reported amounts of assets and liabilities , disclosure of contingent liabilities on the date of financial statements, the reported amount of revenues and expences during the reported period. Although these estimates are based on the managemant's best knowledge of the Current event and actions, uncertainty about these assumption and estimates could result in outcomes different from the estimates. Difference between actual results and estimates are recognised in the period in which the results are known or materialise.Appropriate changes in estimates are made as management becomes aware of changes in circumstances surrounding the estimates. Any revision to accounting estimates is recognised prospectively in current and future periods.

4 Fixed Assets

Fixed Assets(whether Tangible Or Intangible) are stated at cost less accumulated depreciation/amortisation/impairment loss (if any), net of Modvat/cenvat(wherever claimed).The cost of fixed assets includes taxes, duties, freight, borrowing cost, if capitalisation criteria are met and other incidental expenses incurred in relation to their acquisition/bringing the assets for their intended use.

5 Depreciation

The depreciation on fixed assets is provided to the extent of depreciation amount on written down value method . Dpreciation is provided on useful life of the assets at the rates and in the manner prescribed in Schedule-II of the Companies Act,2013.

6 Inventories


Inventories are valued at cost or Net Realizable Value whichever is lower on FIFO basis.

7 Cash & Cash Equivalentts

It comprises of Cash in Hand and balances with scheduled banks.

8 Taxes on Income

Current Tax is amount of tax payable on the taxable income for the year as determined in accordance with the provisions of Income Tax Act. Minimum Alternate Tax (MAT) paid in accordance with the tax laws, which gives future economic benefits in the form of adjustment to future income tax liability, is considered as an asset if there is convincing evidence that the Company will pay normal income tax. Accordingly, MAT is recognised as an asset in the Balance Sheet when it is probable that future economic benefit associated with it will flow to the Company.Deferred tax is recognised on timing differences, being the differences between the taxable income and the accounting income that originate in one period and are capable of reversal in one or more subsequent periods.



For ZENITH DRUGS PVT. LTD.
[Signature]
DIRECTOR

ZENITH DRUGS PVT. LTD.
[Signature]
DIRECTOR

9 Earning Per Share

The basic Earning Per Share ("EPS") is computed by dividing the net profit/(Loss) after tax for the year attributable to the equity shareholder by the weighted average number of equity share outstanding during the year.


For the purpose of calculating diluted Earning Per Share, net profit/(Loss) after tax for the year attributable to the equity shareholder and the weighted average number of equity share outstanding during the year is adjusted for the effects of all dilutive potential equity share.

10 Current/ Non current

All assets and liabilities are presented as current or non-current as per the company's normal operating cycle and other Criteria set out in the Revised Schedule II of the Companies Act 2013. Based on the nature of products and the time Between the acquisition of assets for processing and their realization, the company has ascertained its operating cycle As 12 months for the purpose of Current / Non- Current classification of assets and liabilities

11 Impairment Of Assets:

An asstes is treated as Impaired when the carrying cost of assets exceeds its recoverable value. An impairment loss is charged to the profit and loss statement in the year in which an assets is identified as impaired . The impairment loss recognised in prior accounting period is reversed if there has been a change in the estimate of recoverable amount.




For ZENITH DRUGS PVT. LTD.
[Signature]
DIRECTOR

For ZENITH DRUGS PVT. LTD.
[Signature]
DIRECTOR

NOTES ON FINANCIAL STATEMENT FOR THE YEAR ENDED 31st MARCH, 2020

PARTICULARS	2019-20 AMOUNT	2018-19 AMOUNT		
NOTE-2				
SHARE CAPITAL				
Authorised Share capital				
24,00,000 Equity Shares of Rs. 10/- each (in previous year	24,000,000.00	24,000,000.00		
4,00,000 shares of Rs. 10/- each.)				
	<u>24,000,000.00</u>	<u>4,000,000.00</u>		
Issued, Subscribed & Paid up Share Capital				
400000 Share of Rs. 10 each (Previous year 400000 shares of				
Rs. 10 each)	4,000,000.00	4,000,000.00		
	<u>4,000,000.00</u>	<u>4,000,000.00</u>		
DETAILS OF SHAREHOLDING MORE THAN 5%				
	No of Share	% Holding	No of Share	% Holding
1. Bhupesh Soni	78730	19.68	78730	19.68
2. Smt. Saroj Soni	38050	9.51	38050	9.51
3. Mr. Sandeep Bharadwaj	122030	30.51	122030	30.51
4. Mr. Ajay Singh Dassundi	114690	28.67	114690	28.67
NOTE-3				
RESERVES & SURPLUS				
Profit & Loss Account				
Opening Balance		25,716,071.77		14,374,317.00
Add: Profit & (Loss) for the year		33,998,875.60		11,341,754.77
	TOTAL	<u>59,714,947.37</u>		<u>25,716,071.77</u>
Share Premium		2,000,000.00		2,000,000.00
	TOTAL	<u>61,714,947.37</u>		<u>27,716,071.77</u>



For ZENITH

Sandeep Bharadwaj
DIRECTOR

For ZENITH DRUGS PVT. LTD.

Ben
DIRECTOR

PARTICULARS	2019-20 AMOUNT	2018-19 AMOUNT
NOTE-4		
LONG TERM BORROWINGS		
Secured Loans		
HDFC TERM LOAN 83006168	19,694,916.13	23,663,505.89
HDFC TERM LOAN 83144127	2,155,568.89	3,778,775.40
HDFC TERM LOAN 83598111	-	4,843,500.00
HDFC TERM LOAN 83695222	8,797,244.38	
HDFC TERM LOAN 84306208	8,822,316.24	
PNB HOUSING FINANCE	1,421,025.17	
UBI Car Loan (Honda city)	-	127,405.10
UBI Car Loan (SKODA RAPID)	-	568,236.20
INNOVA CRYSTRA 2.4 LOAN A/C	1,987,653.54	
HDFC CRETA LOAN	1,076,962.55	
HDFC EICHER LOAN 67300823	1,167,197.12	
HDFC LOAN VITARA BREEZA 948133	701,664.19	
LOAN SKODA - 110559194	700,000.00	
TOTAL (A)	46,524,548.21	32,981,422.59

Nature of Security

4.1 The Term loans from HDFC Bank Ltd. Indore is secured :
 Prime Security :- By way of Hyp of Plant and Machinery, Fixed Deposit, Gurantee, Residential Property and Factory.
 Collateral security :- (A) By way of EM on the property at Plot No.2900,Sudama Nagar, Indore, by shri Bhupesh Soni, (B) By way of EM on the property at Plot No.187, IDA Scheme NO. 113 Indore, by shri Ajay Singh Dassundi, (C) By way of EM on the property at Plot No.1625, Scheme NO. 114 Indore, by shri Sandeep Bharadwaj, (D) Equitable mortgage of land and building situated at S.No.72/1 to 72/5, PH No.40(old) And 85 (New) at Gram Muradpura, Teh.Depalpar, dist.Indore admeasuring 43850 Sq.

Terms of Repayment

The total loan amount is to be repaid in EMI A/c 83144127 Rs.159815/-in 37 EMI, A/c 83006168 Rs.518817/-in 68 EMI, A/c 83695222 Rs 102553/- in 60 EMI and A/c 83695208 Rs.203683/- in 36 EMI. Rate of Interest as Applicable by the bank from time to time in Tenure of repayment of loan.


4.1 The loans from HDFC Bank Ltd. Indore is secured : Prime Security :- By way of Hyp of Car and Loading Vehicle (A) Innova Crysta Loan (B) Eicher (C) Vitara Breeza (D) Skoda Rapid (E) Creta

The total loan amount is to be repaid in EMI A/c 95710163 (Innova) Rs. 43695/- in 60 EMI, A/c No. 67300823 (Eicher) Rs. 39241/- in 48 EMI, A/c No. 94813349 (Breeza) Rs. 25533/- in 36 EMI, A/c No. 110559194 (Skoda Rapid) Rs. 22211/- in 36 EMI, A/c No. 92518293 (Creta) Rs. 42008/- in 36 EMI

Unsecured Loans

(From Directors and Shareholders)

Total	20,502,879.00	21,644,126.00
IDFC BANK	1,261,136.44	4,593,240.00
INDUSIND BANK LTD	1,071,298.00	3,807,081.00
KOTAK MAHINDRA BANK	-	4,191,285.00
KOTAK MAHINDRA BANK	6,524,973.00	
MAGMA FINCORP LTD	(21,298.06)	2,938,877.00
RBL BANK	(252,373.00)	3,798,258.00
AXIS BANK LOAN A/C	3,171,302.00	
ICIC LOAN A/C 746589	4,519,236.00	
IDFC FIRST BANK	4,389,910.37	
RBL BANK LOAN A/C	4,306,262.00	
TATA CAPITAL LOAN A/C	4,228,198.00	
TOTAL (B)	49,701,523.75	40,972,867.00
TOTAL (A+B)	96,226,071.96	73,954,289.59



For ZENITH DRUGS PVT. LTD.
[Signature]
 DIRECTOR

For ZENITH DRUGS PVT. LTD.
[Signature]
 DIRECTOR

PARTICULARS	2019-20 AMOUNT	2018-19 AMOUNT
NOTE-5		
DEFERRED TAX ASSETS/LIABILITY		
Opening Balance as on 01-04-2018	1,448,698.00	1,620,580.00
Add/less : Arising during the Year	(373,523.00)	(171,882.00)
Closing Balance as on 31-03-2020	<u>1,075,175.00</u>	<u>1,448,698.00</u>

5.1 During the year under consideration the company has provided for deferred tax liability arising out of timing difference, as per the provisions of Accounting Standard - 22 issued by the Institute of Chartered Accountants of India. As the WDV as per Income Tax is More hence Less depreciation has been charged. Therefore Deferred Tax Assets is arises and same is calculated on difference of Rs. 4135287*26%.

NOTE-6

SHORT TERM BORROWING

Secured Loans

Working Capital repayable on Demand from HDFC Bank

TOTAL

24,506,418.76	20,064,061.29
<u>24,506,418.76</u>	<u>20,064,061.29</u>

6.1 Prime Security :- The Term loans from HDFC Bank Ltd. Indore is secured : Prime Security :- By way of Hyp of Plant and Machinery, Fixed Deposit ,Gurantee, Residential Property and Factory. Collateral security :- (A) By way of EM on the property at Plot No.2900,Sudama Nagar, Indore, by shri Bhupesh Soni, (B) By way of EM on the property at Plot No.187, IDA Scheme NO. 113 Indore, by shri Ajay Singh Dassundi, (C) By way of EM on the property at Plot No.1625, Scheme NO. 114 Indore, by shri Sandeep Bharadwaj. (D) Equitable mortgage of land and building situated at S.No.72/1 to 72/5, PH No.40(old) And 85 (New) at Gram Muradpura,Teh.Depalpuar,dist.Indore admeasuring 43850 Sq.

Stock Statement to be submitted on monthly basis

NOTE-7

TRADE PAYABLES

Sundry Creditors For Goods

Sundry Creditors For Capital Goods

Sundry Creditors For Services

TOTAL

197,262,066.10	163,565,326.00
1,929,126.00	1,172,872.00
30,842,043.43	13,640,064.00
<u>230,033,235.53</u>	<u>178,378,262.00</u>

7.1 The outstanding balances of Trade Payables are subject to confirmation by the respective parties.

NOTE-8

SHORT TERM PROVISIONS

Short Term Provision

Provision For Income Tax

TOTAL

4,536,319.77	2,237,954.00
15,147,528.00	2,482,629.70
<u>19,683,847.77</u>	<u>4,720,583.70</u>

NOTE-10

Other Non Current Assets

Preliminary Exp

Opening Balance

During The Year

Less: Written off during the year

TOTAL

12,000.00	24,000.00
12,000.00	12,000.00
<u>-</u>	<u>12,000.00</u>

NOTE-11

Inventories

(As taken ,Valued & Certified by Management)

Raw Material

Stock in Progress

Finished Stock

33,024,412.00	34,824,248.00
8,025,421.00	8,457,698.00
2,579,172.00	5,603,765.00
<u>43,629,005.00</u>	<u>48,885,711.00</u>

NOTE-12

TRADE RECEIVABLES

More than 6 Month

Others

25,814,949.71	6,366,933.00
228,524,845.25	164,164,999.75
<u>254,339,794.96</u>	<u>170,531,932.75</u>

13.1 Outstanding balances of Trade Receivables are subject to confirmation by the respective parties.

For ZENITH DRUGS PVT. LTD.
Sandeep
DIRECTOR

For ZENITH DRUGS PVT. LTD.
Ag
DIRECTOR

ZENITH DRUGS (P) LIMITED
NOTES ON FINANCIAL STATEMENT FOR THE YEAR ENDED 31st MARCH, 2020

PARTICULARS	2019-20 AMOUNT	2018-19 AMOUNT
NOTE-13		
<u>CASH & CASH EQUIVALENTS</u>		
Cash in Hand	1,739,937.58	1,589,032.83
Balances with Scheduled Banks -		
In Current Account(Bank Of India)	-	8,803.03
In Current Account(State Bank Of India)	1,496,425.89	16,861.89
CA HDFC BANK 194	450,199.27	3,620,583.99
In Current Account(Union Bank Of India)	670,103.12	71,033.22
	4,356,665.86	5,306,314.96

NOTE-14		
<u>SHORT TERM LOANS & ADVANCES</u>		
(Considered Good unless otherwise stated)		
(Recoverable in cash or in kind or for the value to be received)		
Statutory Amounts Recoverable	28,891,279.72	25,804,227.94
Deposit	13,442,329.55	9,637,728.70
Staff Advance	140,000.00	140,000.00
Prepaid Insurance	572,028.00	14,689.00
Advance Tax	1,800,000.00	
TOTAL	44,845,637.27	35,596,645.64

14.1 In the opinion of the Board the current assets, loans and advances have a value on realization in the ordinary course of business at least equal to the amount at which these are stated in the Balance Sheet and that the provision for known liabilities is adequate and not in excess of amount reasonable and necessary. There are no contingent liabilities as on the date of Balance Sheet.

14.2 Outstanding Balances are subject to confirmation by respective parties

REVENUE FROM OPERATION

NOTE-15		
Sale of Product		
Sales	775,177,306.64	521,677,325.03
TOTAL	775,177,306.64	521,677,325.03

NOTE-16		
<u>OTHER INCOMES</u>		
Other Income	514,673.00	222,078.00
Profit on Sales of Bike/Car	105,541.00	956.00
	620,214.00	223,034.00


NOTE-17		
Cost of Materials Consumed		
Opening Stock (Raw Material)	34,505,335.00	
Add: Purchase	534,918,833.46	
Closing Stock (Raw Material)	33,024,412.00	48,885,711.00
Material Consumed	536,399,756.46	48,885,711.00

NOTE-18		
Changes In Inventories Of Stock-In-Trade		
Opening Stock (Finished WIP)	14,380,376.00	23,365,291.00
Closing Stock (Finished WIP)	10,604,593.00	48,885,711.00
	3,775,783.00	(25,520,420.00)

NOTE-19		
Employees Remuneration and Other Benefits		
Salary	29,995,226.00	20,512,838.00
PF	-	47,631.00
Director's Remuneration	8,706,000.00	6,000,000.00
	38,701,226.00	26,560,469.00

19.1 None of the employees of the company has been given salary more than the limit as per act

NOTE-20		
<u>DIRECT EXPENSES</u>		
Total	26,447,967.73	23,791,939.84
	26,447,967.73	23,791,939.84



For ZENITH DRUGS PVT. LTD.

For ZENITH DRUGS PVT. LTD.

ZENITH DRUGS (P) LIMITED
NOTES ON FINANCIAL STATEMENT FOR THE YEAR ENDED 31st MARCH, 2020

PARTICUALRS	2019-20 AMOUNT	2018-19 AMOUNT
NOTE-21		
Interest and Financial Cost	13,122,105.49	9,481,630.14
Total	13,122,105.49	9,481,630.14
NOTE-22		
Other Expenses		
Audit Fees	60,000.00	60,000.00
Advertisement Expenses	69,147.29	-
Bonus	41,500.00	-
Books And Periodical	28,000.00	-
Building Maint.	141,437.00	903,767.00
Postage Exp.	4,664,498.62	1,295,621.58
Consultancy Charges	1,070,101.34	819,125.00
Calibration Charges	58,200.00	58,600.00
Consumable Exp	3,236,859.09	1,631,806.66
Commission Exp	23,716,778.11	12,322,066.42
Conveyance Expenses	24,221.00	-
Diwali Exp.	115,500.00	10,000.00
Diesel & Petrol	1,032,428.73	949,119.30
Depo Rent Chatarpur	10,000.00	-
Drugs Lab Charges (Govt.)	813,366.18	318,866.32
Delay Charges	-	268,307.00
Electricity Exp.	6,290,040.00	5,035,470.00
Electrical Parts	256,716.60	-
Entry Tax	650.00	39,686.00
Excise Paid Agst. Ass.	41,663.00	-
Factory License	28,970.00	-
Factory Exp	341,930.50	131,205.77
Garden Exp.	3,000.00	28,460.00
Gowdown Exp	8,555.00	201,036.00
Goods Damaged& Expired	21,465.00	-
Govt Penalty Tsmside	58,247.00	-
Govt.Mpcg Penalty Exp.	3,025,971.26	-
Govt. Miscs Recovery	379,141.99	-
Govt. Lsp	2,737,862.71	-
Govt. Rajasthan Penalty	9,444.00	-
Hammali At Factory	120,800.00	-
Incentive To Directors	6,000,000.00	-
Incentive Sales	583,378.25	-
R & M Computer Exp.	210,389.24	203,696.69
Repairing & Maintenance 18%	97,215.46	-
Repairing & Maintenance 12%	12,188.00	-
Rent Gowdown	940,000.00	768,000.00
Rates & Taxes	-	45,495.00
Loading & Unloading Exp.	657,624.00	233,741.00
Loan Procecing Fees	708,164.72	-
Legal & Professional Charges	931,910.00	439,984.00
License Mp Polutions Exp.	240,023.60	-
Discount	778,449.70	1,306,054.49
Professional Exp	1,757,321.26	2,986,953.56
Professional Tax	-	2,500.00



For ZENITH DRUGS PVT. LTD.
[Signature]
 DIRECTOR

For ZENITH DRUGS PVT. LTD.
[Signature]
 DIRECTOR

Incentive On Sales	-	2,064,346.93
Incentive Staff	98,506.00	205,347.00
Membership Fees	54,000.00	5,000.00
Maint. To Elec.	296,488.11	206,596.89
Maint. To Machinery	555,527.41	333,356.85
Misc. W/Off	835,304.54	
Misc. Exp.	58,433.00	8,111.00
Medical Check Exp	-	9,800.00
Stationary & Printing Charges	776,271.28	998,287.99
Vehicle Maint.	188,725.00	105,193.00
Tour Exp.	5,069,623.72	3,408,332.00
Tour Pachege Exp.	15,000.00	1,779,038.00
Sales Promotion	3,023,322.46	2,061,681.25
Stipend Exp.	1,358,209.00	1,486,500.00
Short And Late Supply Exp.	-	1,525,198.87
Surcharge On P. Tax	183,632.80	
Telephone, Mobile And Internet Expenses	322,307.32	370,211.52
Convyance Expenses	109,940.18	78,101.00
Convyance Expenses Director	-	10,918.00
Epf Admin And Other Charges	930,658.74	6,000.00
Freight Exp. Gta	18,717,877.00	11,597,587.72
Freight Local And Cartage	1,863,913.88	2,189,407.18
Freight Inward & Outward	965,509.01	
Tender Fees	9,250.00	112,114.56
Validation Charges	18,000.00	33,000.00
Vat Paid Agst. Ass.	32,000.00	19,574.00
Water Exp.	135,760.00	88,850.00
Office Exp	304,544.00	50,213.00
Packing And Forwarding Exp.	(86,496.90)	715,922.12
Repair And Maint.	1,455,066.67	285,248.59
Round Off	(834.48)	1,452.36
Preliminary Exp	12,000.00	12,000.00
Price Difference	7,025,113.37	577,553.84
Staff Welfare	31,818.06	
Stamp Duty Exp	13,000.00	
Security Exp	666,528.92	94,800.00
Penalty On Cst		10,500.00
Penlaty Of Mpeb Exp.	54,467.00	
	106,941,579.74	60,879,924.05

NOTE-23

Earning Per Share (EPS) :

- (i) Net profit/(Loss) after tax for the year attributable to the equity shareholder
- (ii) weighted average number of equity share outstanding during Basic EPS (i)/(ii)

	33,998,875.60	11,341,754.77
	400,000.00	400,000.00
	<u>85.00</u>	<u>28.35</u>



For ZENITH I.L.

[Signature]
DIRECTOR

For ZENITH I.L.

[Signature]
DIRECTOR

ZENITH DRUGS (P) LIMITED
NOTES ON FINANCIAL STATEMENT FOR THE YEAR ENDED 31st MARCH, 2020


PARTICUALRS	2019-20 AMOUNT	2018-19 AMOUNT
NOTE-24 Auditors' remuneration (excluding service tax) and expenses Statutory Auditors: Audit Fees	60,000.00	60,000.00

NOTE-25

Disclosure of related parties / related party transactions :

(A) Related Parties

Parties	Relationship	Nature of Trasaction	
Mr. Bhupesh Soni	Director	5600000/-REM. 526546/- Int. on USL 4411481/-USL	2700000/-REM. 489020/- Int. on USL 5122590/-USL
Mrs. Saroj Soni	Director's Mother	/-Int. on USL 1218017/-USL	131915/-Int. on USL 1218017/-USL
Mrs. Jaywanti Soni	Director's Wife	920000/- Salary 199500/- Int. on USL 1800813/-USL	600000/- Salary 148729/- Int. on USL 1711403/-USL
Mr. Sandeep Bhardwaj	Director	6800000/-REM 368339/-Int. on USL 3508299/-USL	3300000/-REM 180818/-Int. on USL 2994594/-USL
Mrs. Sajoj Bhardwaj	Director's Mother	/-Int. on USL 728215/-USL	78868/-Int. on USL 728215/-USL
Mrs. Priyanka Bhardwaj	Director's Wife	920000/- Salary 118171/-Int. on USL 1175853/-USL	94414/-Int. on USL 969499/-USL
Mrs. Rajni Pachori	Director's Sister	207635/-Int. on USL 1906377/-USL	130980/-Int. on USL 1734386/-USL
Mr. Ajay Singh Dasundi	Director	2306000/-REM. 391345/- Int. on USL 2353408/-USL	372109/- Int. on USL 3799318/-USL 300000/-Salary
Mrs. Lad Kuwar Dasundi	Director' Mother	/-Int. on USL 472431/-USL	51165/-Int. on USL 472431/-USL
Mr. Rajendra Singh Dasundi	Director' Father	122524/-Int. on USL 1097173/-USL 180000/-Salary	127433/-Int. on USL 1062861/-USL 180000/-Salary
Mrs. Anjali Dasundi	Director's Wife	/-Int. on USL 1830812/-USL 920000/-Salary	198283/-Int. on USL 1830812/-USL 600000/-Salary
M/s Biogenesis Corp	Director,s Partnership Firm	Purchase Rs.1768050/- Sales Rs./- Cr Txn-Rs.522436	- - -
M/s Premier Products	Director,s Partnership Firm	Purchase Rs.1768050/- Sales Rs./- Cr Txn-Rs.522436	Purchase Rs.246627 Sales Rs.52864/- Cr Txn-Rs.554531 Dr Txn-Rs.246627
M/s Probiotech	Director,s Partnership Firm	Purchase Rs.62624536/- Sales Rs.45506215/- Cr Txn-Rs.11345447/- Dr Txn-Rs.24470472/-	Purchase Rs.58383254 Sales Rs.38852541/- Cr Txn-Rs.47124301 Dr Txn-Rs.50354481



For ZENITH DRUGS PVT. LTD.
[Signature]
 DIRECTOR

For ZENITH DRUGS PVT. LTD.
[Signature]
 DIRECTOR

ZENITH DRUGS (P) LIMITED
CIN No.- U24231MP2000PTC014465
SCHEDULES FORMING PART OF BALANCE SHEET AS AT 31.03.2020

NOTE 9 : FIXED ASSETS

NAME OF ASSETS	RATE OF DEP. (%)	GROSS BLOCK				DEPRECIATION				NET BLOCK	
		As at 01.04.2019	Addition During the Year	Adjustment / Deduction During the Year	As at 31.03.2020	As at 01.04.2019	For the year ended 31.3.2020	Sales and Adjustment	As at 31.3.2020	As at 31.03.2019	As at 31.3.2020
		Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.
LAND		2,214,675.00	7,277,835.00	-	9,492,510.00	-	-	-	-	2,214,675.00	9,492,510.00
BUILDING	0.00	30,061,377.00	-	-	30,061,377.00	6,194,008.00	2,267,372.00	-	8,461,380.00	23,867,369.00	21,599,997.00
BUILDING NEW SHED	0.00	-	-	-	-	-	-	-	-	-	-
FLAT NO. 102			2,450,000.00	-	2,450,000.00		161,526.00		161,526.00		2,288,474.00
MOTOR VEHICLE - CAR	0.00	1,360,936.00	1,312,704.00	-	2,673,640.00	1,247,255.00	417,228.00	-	1,664,483.00	113,681.00	1,009,157.00
MOTOR CYCLE - HERO	0.00										
MOTOR CYCLE - BAJAJ	0.00	36,855.00	-	-	36,855.00	5,594.00	8,093.00	-	13,687.00	31,261.00	23,168.00
OFFICE FURNITURE	0.00	5,346,309.00	522,917.10	-	5,869,226.10	2,701,123.00	699,606.00	-	3,400,729.00	2,645,186.00	2,468,497.00
TRADEMARK	0.00	311,000.00	47,300.00	-	358,300.00	176,785.00	26,036.00	-	202,821.00	134,215.00	155,479.00
COMPUTER	0.00	1,084,506.00	319,155.00	-	1,403,661.00	819,217.00	288,877.00	-	1,108,094.00	265,289.00	295,567.00
CAR -SKODA RAPID	0.00	1,135,000.00	4,970,592.00	1,135,000.00	4,970,592.00	783,812.00	726,077.00	847,041.00	662,848.00	351,188.00	4,307,744.00
ELECTRIC INSTALLATION	0.00	4,701,092.00	137,133.00	-	4,838,225.00	2,759,827.00	507,913.00	-	3,267,740.00	1,941,265.00	1,570,485.00
PLANT AND MACHINERY	0.00	33,296,069.00	6,455,563.00	-	39,751,632.00	14,910,837.00	4,081,828.00	-	18,992,665.00	18,385,232.00	20,758,967.00
TOTAL Rs.		79,547,819.00	23,493,199.10	1,135,000.00	101,906,018.10	29,598,458.00	9,184,556.00	847,041.00	37,935,973.00	49,949,361.00	63,970,045.00

CAPITAL WORK IN PROGRESS-BUILD
 CAPITAL WORK IN PROGRESS-PLANT

14774745
 11323802
 26098548



For ZENITH DRUGS PVT. LTD.
[Signature]
 DIRECTOR

For ZENITH DRUGS PVT. LTD.
[Signature]
 DIRECTOR

ZENITH DRUGS (P) LIMITED
CIN No.- U24231MP2000PTC014465

GROUPING FORMING PART OF NOTES ON FINANCIAL STATEMENT FOR THE YEAR ENDED 31st MARCH 2020

PARTICULARS	2019-20 INDORE	2018-19 INDORE
NOTE-4		
Unsecured Loans		
(From Directors and Shareholders)		
Rajendra Singh Dassundi	1,097,173.00	1,062,861.00
Ajay Singh Dassundi	2,353,408.00	3,799,318.00
Anjali Dassundi	1,830,812.00	1,830,812.00
Bhupesh Soni	4,411,481.00	5,122,590.00
Jaywanti Soni	1,800,813.00	1,711,403.00
Lad Kunwar Dassundi	472,431.00	472,431.00
Priyanka Bharadwaj	1,175,853.00	969,499.00
Rajni Pachori	1,906,377.00	1,734,386.00
Sandeep Bharadwaj	3,508,299.00	2,994,594.00
Saroj Bharadwaj	728,215.00	728,215.00
Saroj Soni	1,218,017.00	1,218,017.00
TOTAL	20,502,879.00	21,644,126.00

NOTE-8

SHORT TERM PROVISIONS

Prov. For P.F.	191,242.00	7170
Prov. For ESIC	27,380.00	-
Prov. For Electricity	555,007.00	412323
Prov. For Interest	393,539.00	393,539.00
TDS Payable (Interest)	201,813.00	208981
TDS Payable (Professional Fees)	216,209.25	244547
TDS Payable (contract)	92,289	69,046
TDS Payable (Commssion)	597,302.03	565132
TDS Payable (Rent)	7,600.00	7200
TDS Payable (Salary)	2,149,200.00	181688
Prov. For Prof. Tax (Co.)	104,738.00	2,500.00
Prov. For Prof. Tax (Staff)	-	145,828.00
	4,536,319.77	2,237,954.00

NOTE-14

Short Term Loans & Advances

(Considered Good unless otherwise stated)

(Recoverable in cash or in kind or for the value to be received)

Statutory Amounts Recoverable

VAT	397,548.84	397,548.84
TDS	616,066.00	-
TCS	49,310.00	-
GST Credit	27,828,354.88	25,406,679.10
	28,891,279.72	25,804,227.94

For ZENITH DRUGS PVT. LTD.
[Signature]
DIRECTOR


For ZENITH DRUGS PVT. L.L.
[Signature]
DIRECTOR


ZENITH DRUGS (P) LIMITED

CIN No.- U24231MP2000PTC014465

GROUPING FORMING PART OF NOTES ON FINANCIAL STATEMENT FOR THE YEAR ENDED 31st MARCH 2020


PARTICULARS	2019-20 INDORE	2018-19 INDORE
Deposit		
MPCT Deposit	4,000.00	4,000.00
CST PAID ADVANCE	65,814.00	45,814.00
MPLUN Deposit	117,081.00	117,081.00
ADN DEPOSIT	50,000.00	50,000.00
MPSEB Deposit MURADPURA	907,100.00	684,200.00
TNMS Ltd. Deposit	-	180,000.00
Performance Guarantee Karnataka	1,659,276.00	780,809.00
S D with DIC Dewas	9,000.00	41,000.00
FDR Of Vatenary 2141	-	34,316.00
FDR 50300250987298	1,089,250.95	993,524.10
FDR 50300268421772	717,983.20	674,023.50
FDR 50300273683925	602,337.90	565,252.50
FDR 50300273683938	185,834.50	376,211.90
FDR 50300279428552	-	1,103,116.00
FDR 50300319416706	164,341.40	154,024.70
FDR 50300320604592	187,193.80	175,378.00
FDR 531203030003196	321,706.00	303,005.00
FDR 531203030003229	28,004.00	26,342.00
FDR 531203030003375	132,041.00	124,464.00
FDR 531203030003391	139,506.00	131,396.00
FDR 531203030003392	148,949.00	140,288.00
FDR Of 2940	-	28,040.00
FDR 50300344293949	125,211.20	-
FDR 50300366885100	216,778.00	-
FDR 50300370059075	1,159,226.10	-
FDR 50300385205190	382,295.40	-
FDR 50300400409516	148,121.40	-
FDR 531203030003465	26,477.00	-
FDR 50300370059088	857,939.50	-
FDR Of 2941	-	28,042.00
EMD WITH CHATTISGARH	320,800.00	1,455,800.00
EMD HARYANA	50,000.00	50,000.00
EMD WITH MP	20,000.00	200,000.00
EMD U.P.	202,250.00	200,000.00
EMD PATNA	110,000.00	-
EMD RAJASTHAN	200,000.00	200,000.00
EMD WITH KARNATKA	321,000.00	321,000.00
EMD WITH MAHARASHTRA	126,500.00	126,500.00
EMD WITH WEST BENGAL	100,000.00	100,000.00
GODOWN DEPOSIT	132,800.00	132,800.00
GOVT. HOLD	617,211.00	-
DEPOSIT WITH PRECISION COATINGS PVT LTD	55,801.00	55,801.00
BINJRA GIRDHARI LAL	(280,000.00)	-
BANK GURANTEE RAJISTHAN GOVT	203,000.00	-
BANK GURANTEE	352,703.20	-
Security Deposite with MDCGMSC	1,369,797.00	-
Biogenesis Corp (ADVANCE)	95,000.00	-
Insurance Receivable	-	35,500.00
	13,442,329.55	9,637,728.70
	42,333,609.27	35,441,956.64


For ZENITH DRUGS PVT. LTD.

 DIRECTOR

For ZENITH DRUGS PVT. LTD.

 DIRECTOR

ZENITH DRUGS (P) LIMITED
GROUPING FORMING PART OF NOTES ON FINANCIAL STATEMENT FOR THE YEAR ENDED 31st MARCH 2020

PARTICULARS	2019-20 INDORE	2018-19 INDORE
NOTE-20		
Direct Expenses		
Analytical Exp.	886,810.00	1,546,526.00
Pest Control Exp.	52,800.00	47,100.00
Fuel Exp.	-	14,429.00
BaL w/o	1,775,171.43	476,942.25
Boiler Exp.	331,584.64	384,997.00
Man power Exp.	23,401,601.66	21,321,945.59
	26,447,967.73	23,791,939.84
NOTE-21		
Interest and Financial Cost		
Bank Charges	1,127,679.52	901,992.65
Bank Interest	9,032,072.04	6,418,803.49
Interest Other	2,960,641.93	2,128,940.00
Interest on TDS on late payment	1,712.00	31,894.00
	13,122,105.49	9,449,736.14

For ZENITH DRUGS PVT. LTD.

 DIRECTOR

For ZENITH DRUGS PVT. LTD.

 DIRECTOR